Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199754 | 0.82 | CYP1A2 (0.53) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL8215455 | 0.80 | MEN1 (0.40) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL8191594 | 0.78 | AKR1B1 (0.45) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL8201112 | 0.77 | MEN1 (0.43) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL12164480 | 0.75 | AKR1B1 (0.44) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL4752822 | 0.74 | LMNA (0.43) | MEN1KMT2AATMTP53MAPT | |
| SCHEMBL4752501 | 0.74 | AKR1B1 (0.47) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL8193103 | 0.74 | TP53 (0.44) | MEN1KMT2AATMAKR1B1TP53 | |
| SCHEMBL7934462 | 0.74 | KMT2A (0.45) | MEN1KMT2AATMTP53MAPT | |
| SCHEMBL8192915 | 0.74 | AKR1B1 (0.48) | MEN1KMT2AATMAKR1B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825110-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825110-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| WO-2008036755-A1 | SPIRO BENZAZEPINES USED AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | WO | disclosed |
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | AVPR2, AVPR1B, AVPR1A | MEN1 3251/4885KMT2A 4641/4885ATM 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.